

DAFTAR PUSTAKA

1. Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, *et al.* . EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. *Lung Cancer*. 2017;113:37–44.
2. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman, J, Lucian R. Non–Small Cell Lung Cancer, Version 5.2017. *J Natl Compr Cancer Netw*. 2017;15:504–35.
3. O’Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, *et al.* . Uncommon EGFR mutations in advanced NSCLC. *Lung Cancer*. 2017;109:137–44.
4. VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, *et al.* . Tumor biomarker testing in non-small-cell lung cancer: A decade of change. *Lung Cancer*. 2018;116 :90–5.
5. Li K, Yang M, Liang N, Li S. Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution. *Oncol Rep*. 2017;37:1347–58.
6. Chen ZY, Zhao ZW, Zhang XC, Su J, Yang XN, Hong ChZ. EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas. 2012;978–85.
7. Alberg AJ, Brock M V, Samet JM. Epidemiology of lung cancer. In: Broaddus VC, editor. *Murray & Nadel’s Textbook of Respiratory Medicine*. 6th ed. Philadelphia: Elsevier Saunders; 2016. p. 927–30.
8. Massion PP, Sequist L V, Pao W. Biology of lung cancer. In: Broaddus VC, editor. *Murray & Nadel’s Textbook of Respiratory Medicine*. 6th ed. Philadelphia: Elsevier Saunders; 2016. p. 913–6.
9. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development : EGFR gene and cancer. *FEBS J*. 2010;277:301–8.
10. Kemenkes. Pedoman nasional pelayanan kedokteran: Kanker paru. Indonesia KKR, editor. Jakarta: Kementerian Kesehatan Republik Indonesia; 2017. p. 13-15.
11. Silvestri GA, Pastis NJ, Tanner NT, Jett JR. Clinical aspect of lung cancer. In: Broaddus VC, editor. *Murray & Nadel’s Textbook of Respiratory Medicine*. 6th ed. Philadelphia: Elsevier Saunders; 2016. p. 942–3.
12. Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized

treatment strategy. *Cancer Sci.* 2016;107:1179–86.

13. Wu J-Y, Yu C-J, Chang Y-C, Yang C-H, Shih J-Y, Yang P-C. Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer. *Clin Cancer Res.* 2011;17:3812–21.
14. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A *et al.* . Frequency of and variables associated with the EGFR mutation and its subtypes. *Int J Cancer.* 2010;126 :651–5.
15. Castellanos E, Feld E, Horn L. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non–Small Cell Lung Cancer. *J Thorac Oncol.* 2017;12(4):612–23.
16. Jin Y, Chen M, Yu X. Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. *Sci Rep.* 2016;6:1–8.
17. Watanabe S, Minegishi Y, Yoshizawa H, Memondo M, Inoue A, Sugawara S *et al.* . Effectiveness of gefitinib against non-small cell lung cancer with the uncommon EGFR mutation G719X and L861Q. *J Thorac Oncol.* 2014;9 :189–94.
18. Landi L, Cappuzzo F. Irreversible EGFR-TKIs: dreaming perfection. *Transl lung cancer Res.* 2013;2 :40–9.
19. Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, *et al.* . The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. *Lung Cancer.* 2015;87 :169–75.
20. De Pas T, Toffalorio F, Manzotti M, Fumagalli C, Spitaleri G, Catania C *et al.* . Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations. *J Thorac Oncol.* 2011;6 :1895–901.
21. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M *et al.* . Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity. *Cancer Cell.* 2007;11:217–27.
22. Young E, Na E, Surng H, Young J, Lim S, Youn JP. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. *Cancer Biol Ther.* 2016;17:237–45.
23. Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix

- L *et al.* . Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: A multicentre observational study by the French ERMETIC-IFCT network. *Ann Oncol.* 2014;25 :126–31.
24. Hata A, Yoshioka H, Fujita S, Kunimasa K, Kaji R, Imai Y, *et al.* . Complex Mutations in the Epidermal Growth Factor Gene in Non-small Cell Lung Cancer. *J Thorac Oncol.* 2010;5 :1524–8.
 25. Xu M, Xie Y, Ni S, Liu H. The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). *Ann Transl Med.* 2015;3 :96.
 26. Kancha RK, Peschel C, Duyster J. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors. *J Thorac Oncol.* 2011;6 :387–92.
 27. Jusuf A, Wibawanto A, Icksan AG, Syahrudin E, Juniarti, Endardjo S. Kanker Paru (Kanker paru jenis karsinoma bukan sel kecil) Pedoman Diagnosis dan Penatalaksanaan di Indonesia. PDPI 2018 : 23.
 28. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, *et al.* . New response evaluation criteria in solid tumours : Revised RECIST guideline (version 1 . 1). *Eur J Cancer.* 2008;45:228–47.
 29. Syahrudin E, Wulandari L, Muktiati NS, Rima A, Soeroso N, Ermayanti S *et al.* . Uncommon *EGFR* mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. *Lung Cancer: Targets and Therapy* 2018;9 25–34.
 30. Shi J, Yang H, Jiang T, Li X, Zhao C, Zhang L *et al.* . Uncommon *EGFR* mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum- based chemotherapy. *Chin J Cancer Res* 2017;29(6):543-552
 31. Wang Q, Mou J, Yang X, He Y, Li Z, Luo Q, Li Y. EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers? *Lung Cancer: Targets and Therapy.* 2013;4 27–33
 32. Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, Zhang XC, Dong ZY, Wu SP, Jiang BY, Chen HJ, Wang BC, Xu CR, Zhou Q, Mei P, Luo DL, Zhong WZ, Yang XN, Wu YL. Comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. *Lung Cancer* 114 (2017) 96–102
 33. Kuiper JL, Hashemi SMS, Thunnissen E, Snijders PJF, Grünberg K, Bloemena E, Sie D, Postmus PE, Heideman DAM and Smit EF. Non-

classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. *British Journal of Cancer* (2016) 115, 1504–1512

34. Lohinai Z, Hoda MA, Fabian K, Ostoros G, Raso E, Barbai T *et al.* . Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. *Journal of Thoracic Oncology* (2015) 10 : 738 - 746
35. Filosto S, Becker CR, Goldkorn T. Cigarette smoke induces aberrant EGF receptor activation which mediates lung cancer development and resistance to tyrosine kinase inhibitors. *Mol Cancer Ther.* 2012; 11(4): 795–804.
36. Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS *et al.* . Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced adenocarcinomas with G719X/L861Q/S768I mutations. *Journal of Thoracic Oncology.* 2015.10 : 793 - 799
37. Kim SY, Myung JK, Kim HR, Na II, Koh JS, Baek HJ, Kim CH. Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma. *Tuberc Respir Dis* 2019; 82: 62-70
38. Cheng TYD, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. *J Thorac Oncol.* 2016 October ; 11(10): 1653–1671.
39. P3.02b-004 EGFR Mutation in Squamous Cell Advanced NSCLC in Persahabatan Hospital, Jakarta Indonesia. Zaini J, Andarini SL, Syahrudin E, Hudoyo A, Utomo A. *Journal of Thoracic Oncology.* 2017(12)
40. Fatmawati F, Wulandari L. Profil pasien kanker paru jenis karsinoma bukan sel kecil yang mendapatkan inhibitor tirosin kinase sebagai terapi lini pertama di RSUD Dr Soetomo. *Karya Akhir.* 2016
41. Amalia A, Wulandari L. Perbandingan efikasi gefitinib dan erlotinib pada pasien kanker paru jenis karsinoma bukan sel kecil di POSA RSUD Dr Soetomo Surabaya. *Karya Akhir* 2018.
42. Merinda V, Wulandari L. Profil mutasi T790M pasien kanker paru adenokarsinoma yang mengalami progresivitas setelah mendapatkan inhibitor tirosin kinase sebagai lini pertama dengan pemeriksaan circulating tumor DNA. *Karya Akhir.* 2018
43. Labbé C, Leung Y, Silva Lemes JG, Stewart E, Brown C, Cosio AP *et al.* . Real-World EQ5D Health Utility Scores for Metastatic Lung Cancer Patients by Molecular Alteration and Response to Therapy. *Clinical Lung Cancer* 2017: 388-395.e4

44. Xu Jianlin, Jin Bo, Chu Tianqing, Dong Xue, Yang Haitang, Zhang Yanwei, Wu Dan, Lou Yuqing, Zhang Xueyan, Wang Huiming, Han Baohui. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: a real-world study in China. *Lung Cancer*. 2016 (96) : 87-92
45. Agustina, TS, Perbandingan respons terapi gefitinib pada pasien KPKBSK dengan EGFR mutasi exon 19 dan exon 21. *Karya Akhir*. 2017